Literature DB >> 34212374

Antiepileptogenic effects of rapamycin in a model of infantile spasms due to structural lesions.

Ozlem Akman1, Stephen W Briggs1, Wenzhu B Mowrey2, Solomon L Moshé1,3,4, Aristea S Galanopoulou1,3.   

Abstract

OBJECTIVE: Infantile spasms may evolve into persistent epilepsies including Lennox-Gastaut syndrome. We compared adult epilepsy outcomes in models of infantile spasms due to structural etiology (multiple-hit model) or focal cortical inflammation and determined the anti-epileptogenic effects of pulse-rapamycin, previously shown to stop spasms in multiple-hit rats.
METHODS: Spasms were induced in 3-day-old male rats via right intracerebral doxorubicin/lipopolysaccharide (multiple-hit model) infusions. Controls and sham rats were used. Separate multiple-hit rats received pulse-rapamycin or vehicle intraperitoneally between postnatal days 4 and 6. In adult mice, video-EEG (electroencephalography) scoring for seizures and sleep and histology were done blinded to treatment.
RESULTS: Motor-type seizures developed in 66.7% of multiple-hit rats, usually from sleep, but were reduced in the pulse-rapamycin-treated group (20%, p = .043 vs multiple-hit) and rare in other groups (0-9.1%, p < .05 vs multiple-hit). Spike-and-wave bursts had a slower frequency in multiple-hit rats (5.4-5.8Hz) than in the other groups (7.6-8.3Hz) (p < .05); pulse rapamycin had no effect on the hourly spike-and-wave burst rates in adulthood. Rapamycin, however, reduced the time spent in slow-wave-sleep (17.2%), which was increased in multiple-hit rats (71.6%, p = .003). Sham rats spent more time in wakefulness (43.7%) compared to controls (30.6%, p = .043). Multiple-hit rats, with or without rapamycin treatment, had right more than left corticohippocampal, basal ganglia lesions. There was no macroscopic pathology in the other groups. SIGNIFICANCE: Structural corticohippocampal/basal ganglia lesions increase the risk for post-infantile spasms epilepsy, Lennox-Gastaut syndrome features, and sleep dysregulation. Pulse rapamycin treatment for infantile spasms has anti-epileptogenic effects, despite the structural lesions, and decreases the time spent in slow wave sleep.
© 2021 International League Against Epilepsy.

Entities:  

Keywords:  Lennox-Gastaut syndrome; West syndrome; epilepsy; mTOR; sleep

Mesh:

Substances:

Year:  2021        PMID: 34212374      PMCID: PMC8654607          DOI: 10.1111/epi.16975

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   6.740


  51 in total

Review 1.  Animal models of epilepsy and progressive effects of seizures.

Authors:  Miguel A Cortez; Jose-Luis Perez Velazquez; O Carter Snead
Journal:  Adv Neurol       Date:  2006

2.  Carisbamate acutely suppresses spasms in a rat model of symptomatic infantile spasms.

Authors:  Tomonori Ono; Solomon L Moshé; Aristea S Galanopoulou
Journal:  Epilepsia       Date:  2011-07-19       Impact factor: 5.864

3.  Spontaneous Recurrent Absence Seizure-like Events in Wild-Caught Rats.

Authors:  Jeremy A Taylor; Jon D Reuter; Rebecca A Kubiak; Toni T Mufford; Carmen J Booth; F Edward Dudek; Daniel S Barth
Journal:  J Neurosci       Date:  2019-04-10       Impact factor: 6.167

4.  Diagnosis delay in West syndrome: misdiagnosis and consequences.

Authors:  Stéphane Auvin; Adam L Hartman; Béatrice Desnous; Anne-Christine Moreau; Corinne Alberti; Catherine Delanoe; Alfonso Romano; Gaetano Terrone; Eric H Kossoff; Ennio Del Giudice; Luigi Titomanlio
Journal:  Eur J Pediatr       Date:  2012-08-15       Impact factor: 3.183

5.  Long-term outcome in children with infantile spasms treated with vigabatrin: a cohort of 180 patients.

Authors:  Milena Djuric; Ruzica Kravljanac; Biljana Tadic; Nataša Mrlješ-Popovic; Richard E Appleton
Journal:  Epilepsia       Date:  2014-11-06       Impact factor: 5.864

Review 6.  Infantile Spasms: Outcome in Clinical Studies.

Authors:  Raili Riikonen
Journal:  Pediatr Neurol       Date:  2020-02-04       Impact factor: 3.372

7.  The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial.

Authors:  Andrew L Lux; Stuart W Edwards; Eleanor Hancock; Anthony L Johnson; Colin R Kennedy; Richard W Newton; Finbar J K O'Callaghan; Christopher M Verity; John P Osborne
Journal:  Lancet Neurol       Date:  2005-11       Impact factor: 44.182

8.  mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy.

Authors:  Emilio Russo; Rita Citraro; Giuseppe Donato; Caterina Camastra; Rodolfo Iuliano; Salvatore Cuzzocrea; Andrew Constanti; Giovambattista De Sarro
Journal:  Neuropharmacology       Date:  2012-10-22       Impact factor: 5.250

9.  Targeted loss of Arx results in a developmental epilepsy mouse model and recapitulates the human phenotype in heterozygous females.

Authors:  Eric Marsh; Carl Fulp; Ernest Gomez; Ilya Nasrallah; Jeremy Minarcik; Jyotsna Sudi; Susan L Christian; Grazia Mancini; Patricia Labosky; William Dobyns; Amy Brooks-Kayal; Jeffrey A Golden
Journal:  Brain       Date:  2009-05-12       Impact factor: 13.501

10.  De novo mutations in epileptic encephalopathies.

Authors:  Andrew S Allen; Samuel F Berkovic; Patrick Cossette; Norman Delanty; Dennis Dlugos; Evan E Eichler; Michael P Epstein; Tracy Glauser; David B Goldstein; Yujun Han; Erin L Heinzen; Yuki Hitomi; Katherine B Howell; Michael R Johnson; Ruben Kuzniecky; Daniel H Lowenstein; Yi-Fan Lu; Maura R Z Madou; Anthony G Marson; Heather C Mefford; Sahar Esmaeeli Nieh; Terence J O'Brien; Ruth Ottman; Slavé Petrovski; Annapurna Poduri; Elizabeth K Ruzzo; Ingrid E Scheffer; Elliott H Sherr; Christopher J Yuskaitis; Bassel Abou-Khalil; Brian K Alldredge; Jocelyn F Bautista; Samuel F Berkovic; Alex Boro; Gregory D Cascino; Damian Consalvo; Patricia Crumrine; Orrin Devinsky; Dennis Dlugos; Michael P Epstein; Miguel Fiol; Nathan B Fountain; Jacqueline French; Daniel Friedman; Eric B Geller; Tracy Glauser; Simon Glynn; Sheryl R Haut; Jean Hayward; Sandra L Helmers; Sucheta Joshi; Andres Kanner; Heidi E Kirsch; Robert C Knowlton; Eric H Kossoff; Rachel Kuperman; Ruben Kuzniecky; Daniel H Lowenstein; Shannon M McGuire; Paul V Motika; Edward J Novotny; Ruth Ottman; Juliann M Paolicchi; Jack M Parent; Kristen Park; Annapurna Poduri; Ingrid E Scheffer; Renée A Shellhaas; Elliott H Sherr; Jerry J Shih; Rani Singh; Joseph Sirven; Michael C Smith; Joseph Sullivan; Liu Lin Thio; Anu Venkat; Eileen P G Vining; Gretchen K Von Allmen; Judith L Weisenberg; Peter Widdess-Walsh; Melodie R Winawer
Journal:  Nature       Date:  2013-08-11       Impact factor: 49.962

View more
  1 in total

1.  Molecular Mechanism of Overcoming Host Resistance by the Target of Rapamycin Gene in Leptographium qinlingensis.

Authors:  Huanli An; Tian Gan; Ming Tang; Hui Chen
Journal:  Microorganisms       Date:  2022-02-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.